These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 30621018)

  • 1. Chimeric Antigen Receptor T-cell (CAR T) Therapy for Hematologic and Solid Malignancies: Efficacy and Safety-A Systematic Review with Meta-Analysis.
    Yu WL; Hua ZC
    Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30621018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.
    Luo W; Li C; Zhang Y; Du M; Kou H; Lu C; Mei H; Hu Y
    BMC Cancer; 2022 Jan; 22(1):98. PubMed ID: 35073859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.
    Grigor EJM; Fergusson DA; Haggar F; Kekre N; Atkins H; Shorr R; Holt RA; Hutton B; Ramsay T; Seftel M; Jonker D; Daugaard M; Thavorn K; Presseau J; Lalu MM
    BMJ Open; 2017 Dec; 7(12):e019321. PubMed ID: 29288188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: a living systematic review (protocol).
    Leache L; Gutiérrez Valencia M; Saiz LC; Erviti J; Rojas Reyes MX
    Open Res Eur; 2022; 2():38. PubMed ID: 38827275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
    Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
    Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bibliometric analysis of research trends and active research areas in chimeric antigen receptor T cell therapy for hematologic malignancies.
    Zhang G; Deng L; Lu H; Zhang W
    Int J Clin Pharm; 2024 Feb; 46(1):186-194. PubMed ID: 38087131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis.
    Lei W; Xie M; Jiang Q; Xu N; Li P; Liang A; Young KH; Qian W
    Cancers (Basel); 2021 Aug; 13(15):. PubMed ID: 34359816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
    Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
    Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: A meta-analysis.
    Chen LR; Li YJ; Zhang Z; Wang P; Zhou T; Qian K; Fan YX; Guo Y; He GH; Shen L
    Front Oncol; 2022; 12():924208. PubMed ID: 36439485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of chimeric antigen receptor T cells in digestive system cancers: a systematic review and meta-analysis.
    Zhao Z; Zhang J; Bian J; Lu X
    Ann Transl Med; 2022 May; 10(9):508. PubMed ID: 35928759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of chimeric antigen receptor (CAR)-T cell therapy in the treatment of relapsed and refractory multiple myeloma: a systematic-review and meta-analysis of clinical trials.
    Li J; Tang Y; Huang Z
    Transl Cancer Res; 2022 Mar; 11(3):569-579. PubMed ID: 35402175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiotoxicity Associated With Chimeric Antigen Receptor (CAR)-T Cell Therapy for Hematologic Malignancies: A Systematic Review.
    Hanna KS; Kaur H; Alazzeh MS; Thandavaram A; Channar A; Purohit A; Shrestha B; Patel D; Shah H; Mohammed L
    Cureus; 2022 Aug; 14(8):e28162. PubMed ID: 36148204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained efficacy of chimeric antigen receptor T-cell therapy in central nervous system lymphoma: a systematic review and meta-analysis of individual data.
    Zhou J; Wang Z; Wang H; Cao Y; Wang G
    Front Pharmacol; 2023; 14():1331844. PubMed ID: 38328579
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy for Glioblastoma: A Systemic Review and Meta-Analysis.
    Jang JK; Pyo J; Suh CH; Park HS; Chae YK; Kim KW
    Front Oncol; 2022; 12():851877. PubMed ID: 35692797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials.
    Zhu Y; Tan Y; Ou R; Zhong Q; Zheng L; Du Y; Zhang Q; Huang J
    Eur J Haematol; 2016 Apr; 96(4):389-96. PubMed ID: 26115358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive Immunotherapy for B-cell Malignancies Using CD19- Targeted Chimeric Antigen Receptor T-Cells: A Systematic Review of Efficacy and Safety.
    Hao L; Li T; Chang LJ; Chen X
    Curr Med Chem; 2019; 26(17):3068-3079. PubMed ID: 28762313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor modified T-cells for cancer treatment.
    Han X; Wang Y; Han WD
    Chronic Dis Transl Med; 2018 Dec; 4(4):225-243. PubMed ID: 30603741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis.
    Zhou H; Luo Y; Zhu S; Wang X; Zhao Y; Ou X; Zhang T; Ma X
    BMC Cancer; 2018 Sep; 18(1):929. PubMed ID: 30257649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR-T cell combination therapies in hematologic malignancies.
    Zhou D; Zhu X; Xiao Y
    Exp Hematol Oncol; 2024 Jul; 13(1):69. PubMed ID: 39026380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.